Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII

Sam Schulman; Geir E. Tjønnfjord; Richard Wallensten; Uri Martinowitz; Gili Kenet

doi:10.1160/TH05-05-0342

Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII

Sam Schulman, Geir E. Tjønnfjord, Richard Wallensten, Uri Martinowitz, Gili Kenet

Research output: Contribution to journal › Article › peer-review

Abstract

The administration of recombinant activated factor VII (rFVIIa) by continuous infusion has provided a safe and convenient alternative to bolus injections in haemophiliacs with inhibitors, but it has only been reported in a single case with congenital factor VII (FVII) deficiency. The results of 12 consecutive surgical procedures in 7 patients with congenital FVII deficiency are reported here. rFVIIa was always given in continuous infusion, aiming at plasma FVII activity of 0.5 IU/mL. Treatment was given for 2 to 7 days with a mean total dose of 7.8 mg rFVIIa. Blood loss was as expected from the different types of procedures and the only thromboembolic complication was a superficial thrombophlebitis at the infusion site. This mode of substitution was therefore safe, effective and well tolerated.

Original language	English
Pages (from-to)	1177-1180
Number of pages	4
Journal	Thrombosis and Haemostasis
Volume	94
Issue number	6
DOIs	https://doi.org/10.1160/TH05-05-0342
State	Published - Dec 2005
Externally published	Yes

Keywords

Bleeding
Factor VII deficiency
Recombinant factor VIIa
Surgery

Access to Document

10.1160/TH05-05-0342

Cite this

@article{544e6c35ea3f410a8f6dee6470d869d8,

title = "Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII",

abstract = "The administration of recombinant activated factor VII (rFVIIa) by continuous infusion has provided a safe and convenient alternative to bolus injections in haemophiliacs with inhibitors, but it has only been reported in a single case with congenital factor VII (FVII) deficiency. The results of 12 consecutive surgical procedures in 7 patients with congenital FVII deficiency are reported here. rFVIIa was always given in continuous infusion, aiming at plasma FVII activity of 0.5 IU/mL. Treatment was given for 2 to 7 days with a mean total dose of 7.8 mg rFVIIa. Blood loss was as expected from the different types of procedures and the only thromboembolic complication was a superficial thrombophlebitis at the infusion site. This mode of substitution was therefore safe, effective and well tolerated.",

keywords = "Bleeding, Factor VII deficiency, Recombinant factor VIIa, Surgery",

author = "Sam Schulman and Tj{\o}nnfjord, {Geir E.} and Richard Wallensten and Uri Martinowitz and Gili Kenet",

year = "2005",

month = dec,

doi = "10.1160/TH05-05-0342",

language = "אנגלית",

volume = "94",

pages = "1177--1180",

journal = "Thrombosis and Haemostasis",

issn = "0340-6245",

publisher = "Georg Thieme Verlag",

number = "6",

}

TY - JOUR

T1 - Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII

AU - Schulman, Sam

AU - Tjønnfjord, Geir E.

AU - Wallensten, Richard

AU - Martinowitz, Uri

AU - Kenet, Gili

PY - 2005/12

Y1 - 2005/12

N2 - The administration of recombinant activated factor VII (rFVIIa) by continuous infusion has provided a safe and convenient alternative to bolus injections in haemophiliacs with inhibitors, but it has only been reported in a single case with congenital factor VII (FVII) deficiency. The results of 12 consecutive surgical procedures in 7 patients with congenital FVII deficiency are reported here. rFVIIa was always given in continuous infusion, aiming at plasma FVII activity of 0.5 IU/mL. Treatment was given for 2 to 7 days with a mean total dose of 7.8 mg rFVIIa. Blood loss was as expected from the different types of procedures and the only thromboembolic complication was a superficial thrombophlebitis at the infusion site. This mode of substitution was therefore safe, effective and well tolerated.

AB - The administration of recombinant activated factor VII (rFVIIa) by continuous infusion has provided a safe and convenient alternative to bolus injections in haemophiliacs with inhibitors, but it has only been reported in a single case with congenital factor VII (FVII) deficiency. The results of 12 consecutive surgical procedures in 7 patients with congenital FVII deficiency are reported here. rFVIIa was always given in continuous infusion, aiming at plasma FVII activity of 0.5 IU/mL. Treatment was given for 2 to 7 days with a mean total dose of 7.8 mg rFVIIa. Blood loss was as expected from the different types of procedures and the only thromboembolic complication was a superficial thrombophlebitis at the infusion site. This mode of substitution was therefore safe, effective and well tolerated.

KW - Bleeding

KW - Factor VII deficiency

KW - Recombinant factor VIIa

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=29244438433&partnerID=8YFLogxK

U2 - 10.1160/TH05-05-0342

DO - 10.1160/TH05-05-0342

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 16411390

AN - SCOPUS:29244438433

VL - 94

SP - 1177

EP - 1180

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 6

ER -

Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this